Mirum Pharmaceuticals (MIRM) Q1 2026 earnings review
Commercial Machine Fires, But M&A Costs Mask Profitability
Mirum delivered robust Q1 2026 revenue of $159.9M (+43% YoY), driven by accelerating LIVMARLI sales. However, the bottom line tells a Reversing story: a massive $726.3M non-recurring IPR&D charge for the Bluejay acquisition drove a $(790.2)M net loss. Despite the optics of the GAAP loss, management's confidence in the underlying commercial engine is evident through an increased FY26 revenue guidance of $670M (midpoint).
🐂 Bull Case
Top-line growth remains exceptional. LIVMARLI grew 55% YoY, and the Bile Acid portfolio grew 20%. This broad-based performance justified a $30M raise to the midpoint of the FY26 revenue guidance.
Mirum is aggressively transitioning from a liver-focused biotech to a diversified rare genetic disease player. The in-licensing of zilurgisertib for FOP adds a near-term commercial asset with an FDA PDUFA date already set for September 2026.
🐻 Bear Case
The company previously touted achieving GAAP profitability in 25Q3. Now, even after stripping out the $726.3M IPR&D charge and $34.7M in Bluejay-related stock comp, underlying operating expenses reached ~$188M against $160M in revenue—meaning core operations are burning cash again.
Excluding stock-based compensation, core R&D expenses jumped to $73.7M from $41.0M a year ago. As the pipeline expands (brelovitug, zilurgisertib, volixibat), maintaining these programs will structurally elevate cash burn.
⚖️ Verdict: ⚪
Neutral to Bullish. The commercial outperformance is undeniable and de-risks the base business. However, the aggressive M&A strategy is inflating the cost base, delaying sustainable profitability.
Key Themes
LIVMARLI Continues to Accelerate
LIVMARLI remains the undisputed growth engine, generating $113.8M in Q1. Growth is Accelerating to 55% YoY, sequentially up from $106.0M in 25Q4. The momentum is heavily supported by the ongoing PFIC indication rollout and deeper international penetration.
Core Operating Expenses Outpacing Revenue
A concerning divergence contradicts management's narrative of financial strength. While Q1 revenue grew a massive 43% YoY, core operating expenses (excluding the $726.3M IPR&D charge and $34.7M in one-time stock compensation) surged by 48% YoY to ~$188.3M. Reversing the operating leverage achieved in late 2025, the base business generated an implied core operating loss of ~$28M.
Bile Acid Portfolio Provides Stable Floor
The Bile Acid Medicines segment (CHOLBAM, CTEXLI) demonstrated Stable and reliable growth, up 20% YoY to $46.1M. This steady cash generation helps fund the aggressively expanding clinical pipeline.
Aggressive Business Development
Mirum is utilizing its commercial cash flow and recent $268.5M PIPE financing to buy future growth. The licensing of zilurgisertib from Incyte (ALK2 inhibitor for FOP) required only a $16M upfront payment but adds a late-stage asset with a Q3 2026 PDUFA date. This complements the January acquisition of Bluejay Therapeutics and its Phase 3 HDV asset, brelovitug.
Integration Risk and Execution Breadth
With the concurrent Phase 3 programs for brelovitug (HDV), LIVMARLI (EXPAND), and the imminent commercial preparation for zilurgisertib (FOP), the organization is stretching its focus. Brelovitug development alone accounted for $20.8M of Q1 R&D expense, highlighting the heavy capital requirement of the new assets.
Other KPIs
Accelerating from $391.4M at the end of 2025. Despite the high cash burn associated with the Bluejay integration and the $16M upfront payment for zilurgisertib, the balance sheet was heavily reinforced by the $268.5M PIPE financing closed in January 2026.
Stable. Gross margins remain exceptional. Cost of sales actually decreased slightly YoY ($22.1M vs $23.0M in 25Q1) despite a 43% increase in total revenue, pointing to superb unit economics on the commercial products.
Guidance
Decelerating YoY growth, but Accelerating vs prior expectations. Management raised the range from the previous $630-$650M. The new midpoint of $670M implies a 29% YoY growth rate over FY25's $520M. While lower than 2025's ~55% growth, maintaining near-30% growth at this revenue scale is highly impressive.
Key Questions
Timeline to Sustainable Profitability
You achieved GAAP profitability in Q3 2025, but core operating expenses expanded 48% YoY this quarter following the Bluejay integration. When do you expect operating leverage to return, and what is the target timeline for sustained GAAP profitability?
Brelovitug R&D Run-Rate
Brelovitug accounted for nearly $21M in R&D expense this quarter. As the AZURE-1 and AZURE-4 Phase 3 studies progress toward their H2 2026 readouts, should we model this $80M+ annualized run-rate as the new baseline, or will trial costs taper off?
Zilurgisertib Commercial Buildout
With the zilurgisertib PDUFA date fast approaching in September 2026, how much incremental SG&A investment is required to support the FOP launch, given that it targets a different specialist base than your core hepatology products?